Dare Bioscience, Inc. current report, 14 May 2026

Dare Bioscience, Inc. - Form 8-K Summary

Business Context and Reporting Period

Dare Bioscience, Inc. (DARE), a Delaware corporation traded on the Nasdaq Capital Market, filed this Current Report on May 14, 2026. The filing serves to announce the Company's financial results for the quarter ended March 31, 2026.

Key Financial Metrics

The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.

Material Changes

The filing does not disclose specific material changes versus the prior comparable period. The document solely references the issuance of a press release containing the quarterly results.

Guidance, Outlook, and Risks

The filing text does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. The report explicitly states that the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.

Investor Verification Checklist

  • Review Exhibit 99.1 (Press Release) for specific Q1 2026 financial figures including revenue, net loss, and cash position.
  • Verify the Company's cash runway and burn rate as disclosed in the full press release.
  • Check for any updates on clinical trial progress or regulatory milestones mentioned in the omitted press release.
  • Confirm if the Company has elected to use the extended transition period for new accounting standards as an emerging growth company.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.